Batu Biologics Inc., of San Diego, completed a $1 million seed round of funding. Batu leveraged primarily private and angel funding to attain this fundraising goal. Batu Biologics recently filed an investigational new drug application with the FDA seeking to initiate a phase I dose-escalation study for Vallovax in patients with non-small cell lung cancer.